FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896787084> ?p ?o ?g. }

• W2896787084 endingPage "2372" @default.
• W2896787084 startingPage "2369" @default.
• W2896787084 abstract "Future Medicinal ChemistryVol. 10, No. 20 EditorialFree AccessThe emerging field of senotherapeutic drugsVassilios MyrianthopoulosVassilios Myrianthopoulos*Author for correspondence: Tel.: +30 210 72 74 824; E-mail Address: vmyriant@pharm.uoa.gr Department of Pharmaceutical Chemistry, School of Pharmacy, University of Athens, Panepistimiopolis Zografou, Greece Department of Histology & Embryology, Medical School, National & Kapodistrian University of Athens, Athens, Greece PharmaInformatics Unit, ‘Athena’ Research & Innovation Center, 15125 Athens, GreeceSearch for more papers by this authorPublished Online:16 Oct 2018https://doi.org/10.4155/fmc-2018-0234AboutSectionsPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit Keywords: BCL-2cellular senescencedasatinibdrug repurposingmetforminnatural productsNF-κBPI3K/Aktquercetinsenescence-associated secretory phenotypesenolyticssenomorphicstarget-based drug discoveryThe cellular phenomenon of senescence is nowadays widely recognized as one of the hallmarks of the aging process [1,2]. The fundamental characteristic of senescent cells is an irreversible cell cycle arrest. Nonetheless, this proliferative incompetency is not accompanied by apoptosis but by a markedly increased metabolic activity and a highly specific and complex secretory phenotype involving pro-inflammatory cytokines, chemokines, tissue-damaging proteases and growth factors collectively referred to as the senescence-associated secretory phenotype (SASP). Senescence can be induced either as a result of telomere shortening (replicative senescence) or as a response to cellular stressors such as UV radiation, increased levels of ROS species, DNA damage and tumorigenic signals including oncogene expression (cellular senescence) [3]. Due to the underlying biological complexity, identification of senescence is not trivial and to this end, several biomarkers have been utilized. Among them, the most robust are elevated expression levels of the endogenous CDK inhibitors p16INK4a and p21CIP1, increased activity of the lysosomal enzyme senescence-associated β-galactosidase (SA-β-gal) and accumulation of lipofuscin, a nondegradable by-product of aging [4].Senescence was originally understood as a defensive mechanism against proliferation of potentially transformed cells. Subsequently, a number of additional beneficial functions of equal importance such as tissue repair, wound healing and embryonic development came into light [2]. However, it is now well accepted that cellular senescence is causally associated with the onset and progression of a multitude of serious age-related pathologies. Chronic accumulation of senescent cells has been related with neurodegenerative and metabolic diseases, cancer, cardiovascular abnormalities, disorders of the liver, bone and skin, as well as infectious diseases [5]. Indeed, even though senescent cells are normally cleared by the immune system, identification of significant populations of such cells at pathological sites is a consistent finding. The deleterious effects of senescent cells are propagated to the neighboring tissue environment through a multitude of mechanisms that are principally triggered by signals associated with the SASP secretome and include homeostatic aberrations, persistent inflammatory responses, deterioration of the stem cell niche, angiogenesis, induction of epithelial-to-mesenchymal transition, fibrosis and establishment of conditions that promote survival and proliferation of cancer cells [2].In the last 10 years, ground-breaking studies have provided proof of concept that either relieving the burden of senescent cells or suppressing SASP can have a beneficial impact to age-related abnormalities, thus ameliorating the health state of an organism and subsequently increasing life span [6]. To this direction, the discovery that small molecules can act as selective eliminators of senescent cells (senolytics) or as inhibitors of SASP (senomorphics) opened the way to an exciting new field of research aiming at the development of senotherapeutics; drugs that can interfere with and delay the aging process and, consequently, exert a therapeutic effect on age-related disorders [6]. Of seminal importance for establishing senotherapeutics as a highly promising field in drug discovery are studies performed in Mayo Clinic by the Kirkland group [7–10]. The first molecules to be identified as senolytics in 2015 were dasatinib, a kinase inhibitor in clinical use and quercetin, a rather common flavonoid [7]. Both were discovered by following a rational approach involving target validation, genetically modified animals, transcriptomic analysis and bioinformatics. The molecular targets associated with the observed senolytic effects were Eph receptor tyrosine kinases and PI3K/AKT pathway modules, respectively. This discovery prompted further investigations and navitoclax (ABT-263) was the third senolytic to be identified [11]. Navitoclax is a protein–protein interaction inhibitor targeting the BCL-2 family of apoptotic proteins and, in this case, the effect was specifically attributed to inhibition of BCL-XL and BCL-W. The finding that BCL-2 inhibitors can act as senolytics assisted the additional identification of analogs A1331852, A1155463 and ABT-737, investigational drugs that inhibit BCL-2 family members, as senolytics [8]. In the same context, the potential of the flavonol fisetin and the alkaloid piperlongumine against senescent cells was subsequently established [8,12]. The mechanism of action for fisetin is likely related with PI3K/AKT/mTOR and NF-κB pathway modules as in the case of quercetin. On the other hand, the corresponding activity of piperlongumine was shown to be independent of ROS production, the suggested mechanism of action for apoptotic effects demonstrated by this natural product in cancer cells, but rather related with the NF-κB pathway, thus indicating overlapping mechanisms in the senolytic properties of both alkaloids and flavonoids [12].Two key observations were derived by these pioneering studies. The first was that senescent cells are heavily dependent on pro-survival and antiapoptotic pathways and as a result, targeting modules of these signaling cascades can enable selective elimination of aged cells and offer the desired specificity over healthy cells. The second observation was that the senolytic effect appears to be strongly cell-type dependent, thus posing obstacles in developing experimental settings for evaluating senotherapeutics in vitro. These early research efforts provided a firm rationale for evaluating the activity of drug-like molecules against senescence and an increasing number of studies emerged in the following years, including several reports based on in vivo experiments. Natural products continued to emerge as senolytics but interesting senomorphic activities were also recorded for compounds belonging to similar scaffolds. Flavonoids, such as kaempferol and apigenin were attributed with substantial capacities to suppress SASP, possibly by interfering with components of the NF-κB pathway [13]. On the other hand, resveratrol and several synthetic analogs were evaluated as inhibitors of the senescence phenotype and their activity was associated with restoration in the expression of RNA splicing factors, which was notably independent from activation of SIRT1, the enzyme considered as the main mediator of lifespan extension properties attributed to this natural stilbenoid [14]. Polyketides comprise a different class of natural products characterized by a promising senotherapeutic potential. Geldanamycin, tanespimycin and rapamycin were studied in different settings and, regardless of their fair structural similarity, their activities against senescent cells were found to be mediated by markedly different pathways [9,15]. Concerning the two first macrolides, the main mechanism of senolytic action was inhibition of HSP90 coupled with a consequent PI3K/Akt downregulation [9]. Conversely, rapamycin did not act as a senolytic but rather as a potent SASP suppressor through a complex mechanism including inhibition of its main target, mTOR kinase, accompanied by involvement of both Nrf2-dependent and independent modules [15].However, at present the most interesting aspect in the field of senotherapeutics is drug repurposing. Apart from dasatinib and rapamycin, in the last 3 years at least six clinically used drugs have been attributed with potent activity either against survival of senescent cells or SASP. The discovery that the JAK/STAT inhibitor ruxolitinib could alleviate SASP-related dysfunctions and frailty has indicated reduction of activin-A levels as a possible mechanism of action and JAK1/2 kinases as potential targets for senotherapeutic interventions [10]. On the other hand, cotreatment with the HDAC inhibitor panobinostat and taxol was shown to greatly improve therapeutic results of the latter, with recorded synergies mainly attributed to the senolytic potential of panobinostat [16]. Glucocorticoids are a different class of widely used drugs recently characterized by senotherapeutic activity, although rather inconclusively. Whereas cortisol and corticosterone demonstrated a strong capacity to inhibit SASP, the closely related dexamethasone was shown to induce senescence [17,18]. Another widely used drug, the opioid loperamide was also characterized as a senomorphic along with the antipsychotic fluspirilene and a number of dopamine and serotonin antagonists [9]. Finally, the already observed favorable effect of the antidiabetic metformin on lifespan extension was associated with a strong senomorphic action exerted by the biguanide derivative. Regarding the mechanistic aspects of metformin senotherapeutic effects, it was shown that SASP suppression was not directly related with AMPK kinase inhibition, a strong candidate mechanism for the antidiabetic action, but it was associated with inhibition of IKK, a different kinase upstream of NF-κB [19]. The fact that metformin is a well-tolerated drug combined with its potent effect on delaying onset of age-related pathologies prompted the launch of a clinical study in collaboration with FDA, aiming at approval of additional indications for the drug [20].A critical consideration of the current state of the art in the field of senotherapeutics points toward two opposing but not necessarily competing directions. On one hand, a remarkably sophisticated methodological machinery, including reverse pharmacology approaches, chemical biology techniques and advanced model systems has been utilized so far for the identification and mechanistic study of senolytic and senomorphic compounds. On the other hand, pure medicinal chemistry and early stage drug discovery efforts involving hit identification, hit-to-lead optimization and SAR derivation are awkwardly limited, in contrast to the fact that the first relevant molecular targets are already annotated, not to mention the multitude of already available drug-like modulators for many of those proteins. Present-day discoveries suggest an exceedingly promising potential for this area of therapeutics. By considering the demanding, iterative character of systematic medicinal chemistry studies and the time needed to bring such efforts to a complete success, we anticipate that in the near future a number of original drug-like scaffolds along with newly discovered drug targets will emerge, thus establishing medicinal chemistry-oriented development of senescence-targeting small molecules as one of the most attractive fields in the search for new therapeutics.AcknowledgementsThe author would like to thank the editors of the journal for their kind invitation and E Mikros for his critical reading of this manuscript.Financial & competing interests disclosureThe author acknowledges financial support by the H2020-INFRADEV-01-2017 project EPTRI (777554). The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.References1 Munoz-Espin D, Serrano M. Cellular senescence: from physiology to pathology. Nat. Rev. Mol. Cell Biol. 15(7), 482–496 (2014).Crossref, Medline, CAS, Google Scholar2 Van Deursen JM. The role of senescent cells in ageing. Nature 509(7501), 439–446 (2014).Crossref, Medline, CAS, Google Scholar3 Gorgoulis VG, Halazonetis TD. Oncogene-induced senescence: the bright and dark side of the response. Curr. Opin. Cell Biol. 22(6), 816–827 (2010).Crossref, Medline, CAS, Google Scholar4 Hernandez-Segura A, Nehme J, Demaria M. Hallmarks of cellular senescence. Trends Cell Biol. 28(6), 436–453 (2018).Crossref, Medline, CAS, Google Scholar5 Kirkland JL, Tchkonia T. Clinical strategies and animal models for developing senolytic agents. Exp. Gerontol. 68, 19–25 (2015).Crossref, Medline, CAS, Google Scholar6 Childs BG, Gluscevic M, Baker DJ et al. Senescent cells: an emerging target for diseases of ageing. Nat. Rev. Drug Discov. 16(10), 718–735 (2017).Crossref, Medline, CAS, Google Scholar7 Zhu Y, Tchkonia T, Pirtskhalava T et al. The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell 14(4), 644–658 (2015).Crossref, Medline, CAS, Google Scholar8 Zhu Y, Doornebal EJ, Pirtskhalava T et al. New agents that target senescent cells: the flavone, fisetin, and the BCL-XL inhibitors, A1331852 and A1155463. Aging (Albany NY) 9(3), 955–963 (2017).Crossref, Medline, Google Scholar9 Fuhrmann-Stroissnigg H, Ling YY, Zhao J et al. Identification of HSP90 inhibitors as a novel class of senolytics. Nat. Commun. 8(1), 422 (2017).Crossref, Medline, Google Scholar10 Xu M, Tchkonia T, Ding H et al. JAK inhibition alleviates the cellular senescence-associated secretory phenotype and frailty in old age. Proc. Natl Acad. Sci. USA 112(46), E6301–E6310 (2015).Crossref, Medline, CAS, Google Scholar11 Chang J, Wang Y, Shao L et al. Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nat. Med. 22(1), 78–83 (2016).Crossref, Medline, CAS, Google Scholar12 Wang Y, Chang J, Liu X et al. Discovery of piperlongumine as a potential novel lead for the development of senolytic agents. Aging (Albany NY) 8(11), 2915–2926 (2016).Crossref, Medline, CAS, Google Scholar13 Lim H, Park H, Kim HP. Effects of flavonoids on senescence-associated secretory phenotype formation from bleomycin-induced senescence in BJ fibroblasts. Biochem. Pharmacol. 96(4), 337–348 (2015).Crossref, Medline, CAS, Google Scholar14 Latorre E, Birar VC, Sheerin AN et al. Small molecule modulation of splicing factor expression is associated with rescue from cellular senescence. BMC Cell Biol. 18, 31 (2017).Crossref, Medline, Google Scholar15 Wang R, Yu Z, Sunchu B et al. Rapamycin inhibits the secretory phenotype of senescent cells by a Nrf2-independent mechanism. Aging Cell 16(3), 564–574 (2017).Crossref, Medline, CAS, Google Scholar16 Samaraweera L, Adomako A, Rodriguez-Gabin A, Mcdaid HM. A novel indication for panobinostat as a senolytic drug in NSCLC and HNSCC. Sci. Rep. 7, 1900 (2017).Crossref, Medline, Google Scholar17 Laberge RM, Zhou L, Sarantos MR et al. Glucocorticoids suppress selected components of the senescence-associated secretory phenotype. Aging Cell 11(4), 569–578 (2012).Crossref, Medline, CAS, Google Scholar18 Poulsen RC, Watts AC, Murphy RJ, Snelling SJ, Carr AJ, Hulley PA. Glucocorticoids induce senescence in primary human tenocytes by inhibition of sirtuin 1 and activation of the p53/p21 pathway: in vivo and in vitro evidence. Ann. Rheum. Dis. 73(7), 1405–1413 (2014).Crossref, Medline, CAS, Google Scholar19 Moiseeva O, Deschênes-Simard X, St-Germain E et al. Metformin inhibits the senescence-associated secretory phenotype by interfering with IKK/NF-κB activation. Aging Cell 12(3), 489–498 (2013).Crossref, Medline, CAS, Google Scholar20 Barzilai NR. Targeting Aging with Metformin (TAME). Innov. Aging 1(S1), 743–743 (2017).Crossref, Google ScholarFiguresReferencesRelatedDetailsCited BySenotherapeutics for mesenchymal stem cell senescence and rejuvenationDrug Discovery Today, Vol. 28, No. 1Comparative Senescence and Lifespan14 September 2022Skin senescence: mechanisms and impact on whole-body agingTrends in Molecular Medicine, Vol. 28, No. 2The interplay between apoptosis and cellular senescence: Bcl-2 family proteins as targets for cancer therapyPharmacology & Therapeutics, Vol. 230Aging, Cell Senescence, the Pathogenesis and Targeted Therapies of Osteoarthritis23 August 2021 | Frontiers in Pharmacology, Vol. 12The implication of ROCK 2 as a potential senotherapeutic target via the suppression of the harmful effects of the SASP: Do senescent cancer cells really engulf the other cells?Cellular Signalling, Vol. 84The Centenarians: An Emerging Population14 April 2021A natural product solution to aging and aging-associated diseasesPharmacology & Therapeutics, Vol. 216Recent update on discovery and development of Hsp90 inhibitors as senolytic agentsInternational Journal of Biological Macromolecules, Vol. 161Cell Senescence: A Nonnegligible Cell State under Survival Stress in Pathology of Intervertebral Disc DegenerationOxidative Medicine and Cellular Longevity, Vol. 2020The role of senescence in cancer developmentSeminars in Cancer Biology, Vol. 62Metabolite Profiling of Rambutan (Nephelium lappaceum L.) Seeds Using UPLC-qTOF-MS/MS and Senomorphic Effects in Aged Human Dermal Fibroblasts15 May 2020 | Nutrients, Vol. 12, No. 5The link between endometrial stromal cell senescence and decidualization in female fertility: the art of balance15 November 2019 | Cellular and Molecular Life Sciences, Vol. 77, No. 7Exploring the Relevance of Senotherapeutics for the Current SARS-CoV-2 Emergency and Similar Future Global Health Threats8 April 2020 | Cells, Vol. 9, No. 4Transient DNMT3L Expression Reinforces Chromatin Surveillance to Halt Senescence Progression in Mouse Embryonic Fibroblast4 March 2020 | Frontiers in Cell and Developmental Biology, Vol. 8Cellular Senescence and the Kidney: Potential Therapeutic Targets and Tools12 July 2019 | Frontiers in Pharmacology, Vol. 10The chemistry of senescence13 June 2019 | Nature Reviews Chemistry, Vol. 3, No. 7Metformin and Aging: A Review13 September 2019 | Gerontology, Vol. 65, No. 6Prospects of Pharmacological Interventions to Organismal AgingBiomolecular Concepts, Vol. 9, No. 1 Vol. 10, No. 20 Follow us on social media for the latest updates Metrics History Received 11 June 2018 Accepted 8 August 2018 Published online 16 October 2018 Published in print October 2018 Information© 2018 Newlands PressKeywordsBCL-2cellular senescencedasatinibdrug repurposingmetforminnatural productsNF-κBPI3K/Aktquercetinsenescence-associated secretory phenotypesenolyticssenomorphicstarget-based drug discoveryAcknowledgementsThe author would like to thank the editors of the journal for their kind invitation and E Mikros for his critical reading of this manuscript.Financial & competing interests disclosureThe author acknowledges financial support by the H2020-INFRADEV-01-2017 project EPTRI (777554). The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download" @default.
• W2896787084 created "2018-10-26" @default.
• W2896787084 creator A5004953036 @default.
• W2896787084 date "2018-10-01" @default.
• W2896787084 modified "2023-09-23" @default.
• W2896787084 title "The emerging field of senotherapeutic drugs" @default.
• W2896787084 cites W1898081212 @default.
• W2896787084 cites W1932046626 @default.
• W2896787084 cites W1977800604 @default.
• W2896787084 cites W1982481909 @default.
• W2896787084 cites W2047319406 @default.
• W2896787084 cites W2109838416 @default.
• W2896787084 cites W2125855766 @default.
• W2896787084 cites W2128807350 @default.
• W2896787084 cites W2130458932 @default.
• W2896787084 cites W2224886002 @default.
• W2896787084 cites W2550556018 @default.
• W2896787084 cites W2591983504 @default.
• W2896787084 cites W2604477713 @default.
• W2896787084 cites W2612435930 @default.
• W2896787084 cites W2728753106 @default.
• W2896787084 cites W2739438570 @default.
• W2896787084 cites W2752676842 @default.
• W2896787084 cites W2766438319 @default.
• W2896787084 cites W2788548733 @default.
• W2896787084 cites W620553544 @default.
• W2896787084 doi "https://doi.org/10.4155/fmc-2018-0234" @default.
• W2896787084 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30325213" @default.
• W2896787084 hasPublicationYear "2018" @default.
• W2896787084 type Work @default.
• W2896787084 sameAs 2896787084 @default.
• W2896787084 citedByCount "20" @default.
• W2896787084 countsByYear W28967870842018 @default.
• W2896787084 countsByYear W28967870842019 @default.
• W2896787084 countsByYear W28967870842020 @default.
• W2896787084 countsByYear W28967870842021 @default.
• W2896787084 countsByYear W28967870842022 @default.
• W2896787084 countsByYear W28967870842023 @default.
• W2896787084 crossrefType "journal-article" @default.
• W2896787084 hasAuthorship W2896787084A5004953036 @default.
• W2896787084 hasBestOaLocation W28967870841 @default.
• W2896787084 hasConcept C185592680 @default.
• W2896787084 hasConcept C70721500 @default.
• W2896787084 hasConcept C71924100 @default.
• W2896787084 hasConcept C86803240 @default.
• W2896787084 hasConcept C98274493 @default.
• W2896787084 hasConceptScore W2896787084C185592680 @default.
• W2896787084 hasConceptScore W2896787084C70721500 @default.
• W2896787084 hasConceptScore W2896787084C71924100 @default.
• W2896787084 hasConceptScore W2896787084C86803240 @default.
• W2896787084 hasConceptScore W2896787084C98274493 @default.
• W2896787084 hasIssue "20" @default.
• W2896787084 hasLocation W28967870841 @default.
• W2896787084 hasLocation W28967870842 @default.
• W2896787084 hasOpenAccess W2896787084 @default.
• W2896787084 hasPrimaryLocation W28967870841 @default.
• W2896787084 hasRelatedWork W1531601525 @default.
• W2896787084 hasRelatedWork W1990781990 @default.
• W2896787084 hasRelatedWork W2319480705 @default.
• W2896787084 hasRelatedWork W2384464875 @default.
• W2896787084 hasRelatedWork W2606230654 @default.
• W2896787084 hasRelatedWork W2607424097 @default.
• W2896787084 hasRelatedWork W2748952813 @default.
• W2896787084 hasRelatedWork W2899084033 @default.
• W2896787084 hasRelatedWork W2948807893 @default.
• W2896787084 hasRelatedWork W2778153218 @default.
• W2896787084 hasVolume "10" @default.
• W2896787084 isParatext "false" @default.
• W2896787084 isRetracted "false" @default.
• W2896787084 magId "2896787084" @default.
• W2896787084 workType "article" @default.